BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and BioC...

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Elicio The...

Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Elicio Therapeutics (ELTX)

BioCryst ( ($BCRX) ) has issued an announcement. On January 12, 2026, BioCryst Pharmaceuticals reported that preliminary, unaudited net revenue fro...

BioCryst Updates ORLADEYO Revenue Outlook and Guidance

BioCryst ( ($BCRX) ) has issued an update. Effective January 9, 2026, BioCryst Pharmaceuticals raised the U.S. wholesale acquisition cost of its he...

Current Quarter	$0.06	Next Quarter	$0.12
Current Year	$0.21	Next Year	$0.34
QoQ Growth	+100.0%	YoY Growth	+61.9%
3Y EPS CAGR	+25.3%	Target Price	$20.60
Consensus	Buy	Upside	+209.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BCRX	$6.66	+0.45%	2.85M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BCRX	$6.66	+0.5%	2.85M
3
4
5
6

BCRX

BCRX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get BioCryst Pharmaceuticals Inc. Data in Excel

Get BioCryst Pharmaceuticals Inc. Data in Excel